However, sitagliptin, a DPP4 inhibitor, was shown to lower the rate of newly diagnosed CVD in T2DM [29] and we also demonstrated that linagliptin, another DPP4 inhibitor, improved endothelial function, as assessed by flow-mediated dilation in patients with T2DM [30]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.